Small molecule therapies to activate ATF6α in the context of cardiac disease are beginning to be explored in mice with evidence of improved contractile function after ischemia reperfusion injury (Blackwood et al., 2019), but this has yet to be extended to other larger animal models or other cardiac pathologies. The gene discussed is ATF6; the disease is heart disorder.